How to Fix Underperforming Biotech Marketing in 2026

Last Updated: 7/15/2026

Table of contents

• What does underperforming biotech marketing look like?
• Why biotech marketing underperformance goes unnoticed
• How do you diagnose your biotech marketing strategy?
• The five metrics that actually matter
• Common performance problems and their fixes
• How to audit your marketing technology stack
• Aligning marketing and sales to close the gap
• Building a biotech marketing measurement cadence
• What role does content play in performance?
• How XDS approaches biotech marketing diagnostics
• What should you do Monday morning?
• Frequently asked questions

What does underperforming biotech marketing actually look like?

You've invested in email campaigns, paid media, HCP outreach, and website updates. Your dashboard shows plenty of impressions and clicks. But when you check your pipeline or prescription starts, the numbers don't add up.

That disconnect is the hallmark of underperforming biotech marketing. You're generating activity, but not outcomes. And in an industry where development costs run into the billions and marketing windows are tight, activity without impact is a problem you can't afford to ignore.

The challenge is that biotech marketing operates in a multi-actor, regulated environment with lagged data, diverse stakeholders, and compliance requirements that don't exist in other industries. What works for consumer products or even general B2B marketing often falls flat here. For the measurement side of that story, see our healthcare marketing attribution and measurement guide.

Why biotech marketing underperformance goes unnoticed

Many biotech marketing teams don't realize they're underperforming until a product launch stalls or investor interest fades. The reason: traditional marketing metrics hide the real story.

Impressions tell you how many times an ad appeared, not whether the right HCPs saw it. Click-through rates measure curiosity, not clinical intent. Email open rates are inflated by privacy features and don't predict prescriptions. These vanity metrics create a false sense of progress.

Many companies are stuck relying on siloed measurement approaches that only partially capture business impact. The result is unprofitable investments and missed opportunities.

How do you diagnose your biotech marketing strategy?

Diagnosing underperformance starts with asking the right questions. Not "how many people saw our campaign?" but "did our campaign reach the right people and move them toward action?"

Start by mapping your current measurement approach. Are you tracking qualified HCP reach, meaning the number of target physicians who received your message and were eligible to engage? Or are you counting everyone who scrolled past your ad on LinkedIn?

Next, examine your engagement quality. A click means nothing if the visitor bounces in three seconds. Look for meaningful actions: content scroll depth exceeding 60%, form submissions, sample requests, or rep-scheduled calls. These signals indicate genuine interest.

Ask these diagnostic questions

Pull your marketing team together and work through these questions honestly. Where you hesitate or lack data, you've found a gap.

Are your target audiences clearly defined by specialty, decile, territory, and consent status? Do you know your reach gap, meaning the percentage of target HCPs you're not reaching at all? Can you measure incremental prescription lift from specific campaigns, or are you guessing based on correlation?

Are your marketing and sales teams sharing data, or operating in silos with different KPIs? How long does it take from first engagement to first prescription fill, and do you know where the delays occur?

The five metrics that actually matter for biotech marketing

Once you've diagnosed the symptoms, you need the right metrics to guide your recovery. Forget impressions and clicks. Here are the five KPIs that predict real business outcomes.

Qualified HCP reach and frequency

This metric counts unique physicians within your target universe who received your message and were eligible to engage, meaning they're in-target, consented, and compliant. Track exposure frequency in bands: 1-2, 3-5, 6-9, and 10+ touches.

Too little frequency means you're not breaking through. Too much means you're burning out your audience and risking opt-outs. Use this metric to close coverage gaps among priority specialties and coordinate with field teams to avoid over-touching top deciles.

Omnichannel engagement quality

Create a weighted score that favors interactions tied to real intent. An email read for eight seconds might earn one point. Content scroll depth over 60% earns two points. A form submission earns three. A rep-scheduled call earns four. A sample request earns five.

This Omnichannel Engagement Quality score tells you which content and channels drive meaningful engagement versus which ones generate empty clicks. Use it to promote high-yield content and train your next-best-action models.

Incremental prescription lift

This is the causal impact of your campaign on new starts or total prescriptions, measured with holdouts or matched-market controls. Run tests at the physician, territory, or geographic level. Compare treatment groups against control groups that didn't receive the campaign.

Without incremental lift measurement, you can't separate your marketing's impact from market trends, seasonality, or sales rep activity. You're flying blind on whether your spend is actually driving results.

Time-to-therapy and early persistency

Time-to-therapy measures days from an index action (like an e-prescription or sample request) to first fill. Early persistency tracks refill rates at 30, 60, and 90 days. These metrics reveal access barriers and adherence problems.

If your time-to-therapy is slow, you have friction in the path to treatment: prior authorization delays, copay shock, or pharmacy channel issues. If early persistency drops, patients are abandoning therapy before it can work.

Cost per qualified action and lifetime value

Cost per qualified action measures what you spend to produce an action that predicts prescription starts, not just any action. Pair this with lifetime value to understand the long-term payback from your acquisition efforts.

Use these economics metrics to shift budget toward channels with low cost per qualified action and healthy lifetime value ratios. Set stop-loss rules for tactics that exceed thresholds without showing improvement.

Common biotech marketing performance problems and their fixes

Once you're measuring the right things, patterns emerge. Here are the most common problems we see and how to address them.

Reach gaps in priority segments

You might find that only 54% of priority specialists receive three or more touches from your campaign. The rest never hear from you, or hear from you once and forget.

Fix this by running a gap analysis on your target list against your actual reach data. Identify which specialties, territories, or deciles are underserved. Then reallocate spend and coordinate with field sales to close those gaps before judging overall campaign performance.

High activity, low engagement quality

Your clicks look fine, but engagement quality scores are weak. People are clicking but not reading, scrolling, or taking action. This usually means your content isn't resonating, or you're reaching the wrong audience.

Test different content formats and messages. Video education followed by rep follow-up might generate three times more predictive actions than email alone. Identify which sequences work and double down on them.

Prescription lift is flat despite spending

You're spending, but new prescription starts aren't moving. Before cutting budget, run a proper incrementality test with holdout groups. You might discover that certain channels drive lift while others don't, even if both show similar activity metrics.

A geo test might reveal that your sequence of video education plus rep follow-up generates 7% incremental lift compared to email-only territories. That insight lets you reallocate toward what works.

Slow time-to-therapy stalls your pipeline

Patients are getting prescriptions, but fills are delayed. Cohort your time-to-therapy data by pharmacy channel and payer mix. You might find that specialty pharmacies with high prior authorization burdens cause most of the delays.

Address this with targeted interventions: hub outreach, prior authorization automation, and copay messaging timed to the benefit verification window. Teams that reduce abandonment by 8-10% see meaningful improvements in patient outcomes and commercial results.

How to audit your biotech marketing technology stack

Underperformance often hides in your technology stack. Disconnected systems, poor data hygiene, and missing integrations prevent you from seeing the full picture.

Check your identity graph

Can you connect HCP events, consent status, and outcomes across your CRM, media platforms, web analytics, event systems, and hub data? Without a unified identity graph, you're measuring fragments instead of journeys.

XDS works with biotech companies to build connected data architectures that link marketing touchpoints to prescription outcomes. This foundation makes all your measurement efforts more accurate and actionable. Our HIPAA-compliant GA4 setup guide covers the web analytics layer specifically.

Evaluate your consent management

Are you tracking opt-in growth, channel permissions, and decay? Are your eligibility rules built into both activation and analytics? Consent isn't just a compliance checkbox. It's a prerequisite for meaningful measurement.

If you're counting non-permissioned impressions as reach, your metrics are inflated. Clean this up by building consent gating into all outreach and analytics workflows.

Assess your attribution approach

Are you relying solely on last-click attribution? That approach misses the multi-touch reality of biotech buying journeys. Blend test-and-control incrementality testing with marketing mix modeling for coverage.

Time-shift your marketing inputs to account for outcome lags. A campaign that runs in January might influence prescriptions in March. If you're measuring both in real-time, you'll miss the connection.

Aligning marketing and sales to fix performance gaps

Siloed organizations create siloed measurement. When marketing and sales have different KPIs, insights get segregated instead of shared. Finance, analytics, and consumer insights operate independently, preventing a common measurement toolkit. Our post on AI sales enablement for healthcare and pharma covers the field-medical and rep side of the same coordination problem.

Create cross-functional measurement teams

Break down the walls between marketing, sales, commercial analytics, and finance. Form cross-functional teams with clearly defined roles for modeling, consumer insights, and test-and-learn activities.

These teams should meet regularly to interpret results and drive decisions together. When everyone sees the same data and shares accountability for outcomes, coordination improves dramatically.

Establish shared KPIs

Agree on a single set of metrics that both marketing and sales care about. Qualified reach, engagement quality, and incremental lift should inform both functions. When marketing optimizes for reach and sales optimizes for close rates without coordination, you get inefficiency.

Build dashboards that roll up from operational metrics through tactical adjustments to strategic decisions. Each level should answer "what should we do next?" not just "what happened?"

Building a biotech marketing measurement cadence

Fixing underperformance isn't a one-time project. It requires building measurement into your operating rhythm at multiple time horizons.

Weekly operational reviews

Track qualified reach, frequency bands, and engagement quality scores weekly. This lets you make real-time adjustments to campaigns while they're running, pausing tactics that aren't working and scaling those that are.

Set stop-loss rules: if cost per qualified action exceeds your threshold without engagement quality improvement in a set number of weeks, pause and investigate.

Monthly tactical adjustments

Review time-to-therapy, early persistency, and incremental lift monthly. These metrics move more slowly but reveal whether your strategic bets are paying off.

Use monthly reviews to make course corrections on campaign spending levels, channel mix, timing, and messaging. Don't wait for quarterly planning cycles to respond to clear signals.

Quarterly strategic planning

Pick one North Star KPI per quarter. In Q1, focus on closing reach gaps. In Q2, drive engagement quality improvements. In Q3, run lift testing experiments. In Q4, focus on economics and efficiency.

This focused approach prevents the measurement overwhelm that leads teams to track everything and act on nothing. Each quarter builds on the last.

What role does content play in biotech marketing performance?

Content strategy failures often masquerade as channel or targeting problems. You might have the right audience and the right platforms, but if your content doesn't resonate, performance will suffer. This is where AI-search visibility increasingly matters as well, since HCPs and patients now start research inside ChatGPT and Perplexity. See our post on AI visibility for SEO and our GEO for healthcare brands deep dive.

Evaluate content by engagement quality

Score each content piece by its contribution to meaningful engagement actions. Which assets drive scroll depth, time on page, form completions, and downstream actions? Which ones get clicks but no follow-through?

Retire low-performing content and invest in creating more of what works. If video explainers outperform white papers in driving qualified actions, shift your production resources accordingly.

Match content to the buyer journey

Different stakeholders need different content at different stages. Investors want market size, competitive positioning, and ROI potential. Healthcare professionals need clinical data, safety profiles, and patient outcomes. Patients want reassurance, accessibility information, and support resources.

Audit your content library against these needs. Gaps in mid-funnel content, where AI surfaces initial research but fails to support consultative conversations, are common in biotech. Fill them with educational assets that move prospects toward decision. For the review-cycle side of content production, see MLR workflow automation.

How XDS approaches biotech marketing diagnostics

XDS brings a practitioner's perspective to biotech marketing performance challenges. We've worked with biotech and pharmaceutical clients across development stages, from pre-launch positioning through commercial maturity.

Our approach starts with data architecture. You can't diagnose what you can't measure, and you can't measure accurately without connected systems. We help clients build identity graphs that link HCP touchpoints to business outcomes.

From there, we establish the measurement framework: qualified reach, engagement quality, incremental lift, time-to-therapy, and cost per qualified action. We set benchmarks, build dashboards, and create the operating cadence to act on insights.

The goal isn't just better reporting. It's better decisions. Every metric should answer a question about what to do next. When your measurement system drives action, underperformance becomes fixable rather than mysterious. 

What should you do Monday morning?

If you've recognized your own situation in this guide, here's where to start. You don't need to overhaul everything at once. Pick one area and make progress.

Run a reach gap analysis

Pull your target HCP list and compare it against your actual reach data. What percentage of priority physicians received at least three touches in the past quarter? Where are the gaps by specialty, territory, or decile?

This single analysis often reveals that significant portions of your target audience have never been meaningfully engaged. You can't convert people you never reach.

Score your recent campaigns on engagement quality

Take your top five campaigns from last quarter and score them on engagement quality, not clicks, but meaningful actions. Which ones drove scroll depth, form completions, sample requests, or rep meetings?

Rank them and ask why the winners worked. Was it the content format, the channel, the timing, or the audience? Apply those lessons to your next campaign.

Identify one measurement gap to close

Where do you lack data? Maybe you can't connect marketing exposure to prescription outcomes. Maybe you don't know your time-to-therapy by pharmacy channel. Maybe you've never run an incrementality test with holdouts.

Pick one gap and commit to closing it this quarter. Progress on measurement compounds over time.

Frequently asked questions about biotech marketing performance

What are the first signs of underperforming biotech marketing?

High activity metrics paired with flat business outcomes signal underperformance. You see plenty of impressions and clicks, but new prescription starts, investor interest, or HCP engagement don't increase.

XDS helps biotech teams connect marketing activity to business outcomes by building measurement frameworks that track what actually matters. When you measure qualified reach instead of impressions, the real picture becomes clear.

Why do traditional marketing metrics fail in biotech?

Biotech marketing operates with lagged data, diverse stakeholders, and regulatory constraints that make consumer metrics irrelevant. A click doesn't indicate clinical intent, and an impression doesn't mean a qualified HCP saw your message.

You need metrics designed for the biotech context: qualified reach, engagement quality scores, incremental prescription lift, and time-to-therapy measurements that reflect your actual business outcomes.

How often should biotech companies audit their marketing performance?

Build measurement into your operating rhythm at three levels. Review operational metrics like reach and engagement weekly. Assess tactical metrics like time-to-therapy monthly. Conduct strategic reviews of lift testing and economics quarterly.

This cadence lets you catch problems early while maintaining focus on longer-term strategic goals.

What technology is needed for proper biotech marketing measurement?

You need a unified identity graph connecting CRM, consent management, media platforms, web analytics, event systems, and prescription data. Without this foundation, you measure fragments instead of journeys.

XDS works with biotech clients to build connected data architectures that make accurate measurement possible across channels and touchpoints. See our healthcare marketing attribution and measurement guide for the framework.

How do you measure the ROI of biotech marketing campaigns?

True ROI measurement requires incrementality testing, comparing treatment groups against holdout controls to isolate your campaign's causal impact on prescriptions. Without holdouts, you're measuring correlation, not causation.

Combine incrementality testing with cost per qualified action and lifetime value analysis to understand both the efficiency and long-term payback of your marketing investments.

What's the biggest mistake biotech marketers make with measurement?

Tracking vanity metrics like impressions and clicks while ignoring qualified reach and engagement quality. These activity metrics create false confidence while real performance problems go unaddressed.

The fix is shifting your measurement framework toward metrics that predict business outcomes, not just metrics that are easy to track.

How can biotech companies improve HCP engagement?

Focus on engagement quality over quantity. Identify which content formats and channel sequences drive meaningful actions like content depth, form submissions, and rep meetings. Double down on what works.

XDS helps biotech brands create content strategies and channel mixes that resonate with HCP audiences, driving qualified engagement that leads to prescriptions.

Working with XDS on biotech marketing performance

If you've read this far and recognized your own team's patterns, XDS can help you turn diagnostic work into a working measurement operation. We map the current state, build the identity graph, install the five-metric framework, and stand up the weekly, monthly, and quarterly cadence that keeps it healthy.

Related reading: pharma SEO in 2026, AI in healthcare marketing, optimizing paid media for healthcare, how to choose a healthcare marketing agency.

Get in touch with XDS to talk through a biotech marketing performance audit.